Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Por:
Strober B., Paul C., Blauvelt A., Thaçi D., Puig L., Lebwohl M., White K., Vanvoorden V., Deherder D., Gomez N.N., Eyerich K.
Publicada:
1 ene 2023
Ahead of Print:
12 may 2023
Resumen:
BACKGROUND: Bimekizumab is a monoclonal IgG1 antibody that inhibits interleukin-17A/F. Bimekizumab is more efficacious than secukinumab over 1 year in the treatment of psoriasis. OBJECTIVE: Evaluate the safety and efficacy of bimekizumab through 2 years in patients with moderate to severe plaque psoriasis. METHODS: The BE RADIANT phase 3b randomized controlled trial consisted of a 48-week double-blinded period, where patients received bimekizumab (320 mg every 4 or 8 weeks) or secukinumab (300 mg weekly to Week 4, then every 4 weeks), and an open-label extension (OLE). From Week 48, all patients received bimekizumab in the OLE. RESULTS: At Week 48, more patients achieved complete skin clearance (PASI 100; modified non-responder imputation) with bimekizumab than secukinumab (74.8% vs 52.8%). PASI 100 responses were maintained to Week 96 in continuous bimekizumab patients (70.8%); patients who switched from secukinumab to bimekizumab had increased rates at Week 96 (76.6%). The most common adverse events were: nasopharyngitis, oral candidiasis, and urinary tract infection. Safety data were consistent with the known safety profile of bimekizumab. LIMITATIONS: Limited racial diversity; overlap with the COVID-19 pandemic. CONCLUSIONS: High PASI 100 responses achieved with bimekizumab over 48 weeks were sustained through Week 96; secukinumab patients who switched to bimekizumab achieved similar responses by Week 96.
Filiaciones:
Strober B.:
Department of Dermatology, Yale University, New Haven, Connecticut, United States
Central Connecticut Dermatology Research, Cromwell, Connecticut, United States
Paul C.:
Toulouse University and INSERM Infinity, Toulouse, France
Blauvelt A.:
Oregon Medical Research Center, Portland, Oregon, United States
Thaçi D.:
Insititute and Centre for Inflammation Medicine, University of Lübeck, Lübeck, Germany
Puig L.:
Hospital de la Santa Creu I Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain
Lebwohl M.:
Icahn School of Medicine at Mount Sinai, New York, New York, United States
White K.:
UCB Pharma, Slough, United Kingdom
Vanvoorden V.:
UCB Pharma, Brussels, Belgium
Deherder D.:
UCB Pharma, Braine-l'Alleud, Belgium
Gomez N.N.:
Department of Dermatology, UCB Pharma, Monheim, Germany
Eyerich K.:
Department of Dermatology, Medical Center, University of Freiburg, Freiburg, Germany
hybrid, All Open Access; Hybrid Gold
|